THE ASSOCIATION BETWEEN THE HIGH-FLOW NASAL CANNULA TECHNIQUE DURING BRONCHOSCOPY AND THE MAINTENANCE OF PERIPHERAL OXYGEN SATURATION (SPO₂): A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES
TL;DR
The benefit of HFNC was consistent in direction across sedation depth, procedure type, baseline risk and comparator device, although heterogeneity in magnitude was substantial and was driven chiefly by trials with matched nominal FiO₂ or very high control-arm risk.
Abstract
Introduction: Peri-procedural hypoxaemia is the most frequent physiological complication of flexible bronchoscopy and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), particularly under procedural sedation, bronchoalveolar lavage (BAL) and in patients with limited respiratory reserve. High-flow nasal cannula (HFNC) delivers heated, humidified gas at up to 60–80 L/min with a stable fraction of inspired oxygen (FiO₂), nasopharyngeal dead-space washout and a flow-dependent positive airway pressure. We aimed to quantify the association between HFNC use during bronchoscopy and the maintenance of peripheral oxygen saturation (SpO₂), with emphasis on evidence published in the last 15 years.1–3 Methods: The study strictly adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. Randomised controlled trials (RCTs), cohort, case–control, cross-sectional and other prospective or retrospective observational studies comparing HFNC with conventional oxygen therapy (COT), non-invasive ventilation (NIV) or different HFNC flows during bronchoscopy were eligible.4–6 Results: Thirty-two primary studies (23 RCTs and 9 observational/non-randomised studies; 4,572 participants; 2012–2026) were included. In 12 adult RCTs (2,318 participants), HFNC reduced intraprocedural desaturation (SpO₂ < 90%) from 39.9% to 15.0% (risk ratio [RR] 0.34, 95% CI 0.25–0.47; I² = 72%; prediction interval 0.12–0.95), corresponding to 262 fewer events per 1,000 patients and a number needed to treat of 3.8. Including the PROSA-2 trial and two observational studies (odds ratio 0.20, 95% CI 0.14–0.28) did not change the inference. HFNC increased nadir SpO₂ by 4.95 percentage points (95% CI 2.89–7.00; five RCTs), reduced procedure interruption (RR 0.39, 0.28–0.54; I² = 13%), airway manoeuvres or support escalation (RR 0.40, 0.24–0.67) and severe hypoxaemia/advanced rescue (RR 0.31, 0.16–0.63). A monotonic flow–response relationship was observed, with a reported ED₉₅ of approximately 43 L/min. In moderate-to-severe hypoxaemic respiratory failure, NIV provided better oxygenation than HFNC. The effect was robust across all sensitivity analyses; certainty was moderate for desaturation and procedure interruption.7–13 Discussion: The benefit of HFNC was consistent in direction across sedation depth, procedure type (EBUS-TBNA vs. non-EBUS bronchoscopy), baseline risk and comparator device, although heterogeneity in magnitude was substantial and was driven chiefly by trials with matched nominal FiO₂ or very high control-arm risk. Neutral trials under conscious sedation and matched FiO₂ suggest that part of the benefit derives from superior and more stable oxygen delivery, while physiological studies support additional contributions from preserved end-expiratory lung volume and dead-space washout.14–16 Conclusion: HFNC during bronchoscopy is associated with clinically meaningful preservation of SpO₂, fewer hypoxaemic events and fewer procedure interruptions, with moderate certainty. HFNC at ≥ 45–60 L/min should be preferred for sedated, prolonged or BAL-containing procedures and for patients at increased risk, whereas NIV/CPAP remains preferable in established moderate-to-severe hypoxaemic respiratory failure. Adequately powered, blinded-outcome multicentre trials with standardised desaturation definitions and patient-important endpoints are required.2,17